Regulatory agilities impacting review timelines for Pfizer/BioNTech’s BNT162b2 mRNA COVID-19 vaccine: a retrospective study

Regulatory agilities impacting review timelines for Pfizer/BioNTech’s BNT162b2 mRNA COVID-19 vaccine: a retrospective study

The appropriate use of regulatory agilities has the potential to accelerate regulatory review, utilize resources more efficiently and deliver medicines and vaccines more rapidly, all without compromising quality, safety and efficacy. This was clearly demonstrated during the COVID-19 pandemic where r...

Full description

Bibliographic Details
Main Authors: Prisha Patel, Judith C. Macdonald, Jayanthi Boobalan, Matthew Marsden, Ruben Rizzi, Marianne Zenon, Jinma Ren, Haitao Chu, Joseph C. Cappelleri, Satrajit Roychoudhury, Julie O’Brien, Konoha Izaki-Lee, Donna Boyce
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Medicine
Subjects:
regulatory
agilities
reliance
convergence
vaccines
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1275817/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1275817/full

Similar Items